Prolia (Denosumab) Cost in Louisiana 2026

What Does Prolia (Denosumab) Cost in Louisiana in 2026?

Brand-name Prolia carries an Amgen wholesale acquisition cost of approximately $1,500 per 60 mg prefilled syringe. Because patients receive one injection every six months, the annual list-price exposure is close to $3,000 before any insurance or discount is applied. Louisiana retail pharmacy cash prices in 2026 closely track that list price, with little variation across major chains.

Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL), blocking osteoclast formation and reducing bone resorption [1]. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high risk of fracture [2]. Its efficacy rests heavily on the FREEDOM trial (N=7,868), which showed a 68% relative reduction in new vertebral fractures over 36 months (7.2% placebo vs. 2.3% denosumab, P<0.001) and a 40% reduction in hip fractures [3]. That fracture-reduction profile makes discontinuation risky: stopping denosumab without transitioning to another antiresorptive can trigger rapid bone mineral density loss and rebound vertebral fractures within 12 months [4].

Because no FDA-approved generic denosumab exists in 2026, patients cannot substitute a cheaper biosimilar at the pharmacy counter. Cost management therefore depends on insurance tier placement, manufacturer savings programs, or compounded formulations from 503A pharmacies.

For uninsured Louisianans paying cash, Good Rx and similar platforms rarely offer discounts on biologics like Prolia below the list price. Patients should budget the full ~$1,500 per dose unless one of the pathways below applies.

Does Louisiana Medicaid Cover Prolia (Denosumab)?

Louisiana Medicaid does not cover Prolia for the osteoporosis indication as of 2026. Physicians who have attempted prior authorization for postmenopausal osteoporosis under Louisiana Medicaid (Healthy Louisiana) consistently find denosumab excluded from the preferred drug list for that diagnosis.

Coverage may exist under different diagnosis codes. Louisiana Medicaid does list denosumab (as Xgeva, the 120 mg oncology formulation) for prevention of skeletal-related events in bone metastases from solid tumors and multiple myeloma [5]. The 60 mg Prolia formulation for osteoporosis, however, is not a covered benefit under most Healthy Louisiana managed care plans. Patients enrolled in dual-coverage Medicare/Medicaid may find Part D or Part B coverage instead (see the Medicare section below).

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "Denosumab is recommended as a first-line pharmacological treatment option for women at high fracture risk" [6]. That clinical recommendation does not automatically translate into Medicaid formulary inclusion at the state level, and Louisiana's exclusion leaves a meaningful coverage gap for low-income patients.

Advocates may petition Healthy Louisiana managed care organizations (Aetna Better Health of Louisiana, Humana Healthy Horizons, Molina Healthcare, United Healthcare Community Plan, Wellcare) individually, but approval for the osteoporosis indication is uncommon based on published formulary data.

How Does Medicare Cover Prolia (Denosumab) in Louisiana?

Medicare coverage depends on where and how the injection is administered, a distinction that matters enormously for cost. When a physician or nurse practitioner administers Prolia in a clinical office setting, Medicare Part B typically covers it as an outpatient drug, applying the Part B 20% coinsurance after the annual deductible [7]. At a $1,500 list price, that 20% coinsurance equals $300 per dose, or $600 per year, before any supplemental coverage.

When a patient self-injects or obtains the drug from a retail or mail-order pharmacy, Medicare Part D governs coverage. Tier placement varies by plan. Most Part D plans in Louisiana place Prolia in Tier 4 or Tier 5 (specialty drug tier), generating copays of $80 to $200 or more per dose depending on plan design and deductible phase [8].

Patients with a Medigap (Medicare Supplement) policy that covers Part B coinsurance may owe little or nothing for office-administered injections. The Louisiana Department of Insurance maintains a Medicare Supplement comparison tool at ldh.la.gov that lists participating plans by parish [9].

The Low Income Subsidy (LIS, also called Extra Help) under Part D caps drug costs for qualifying Medicare beneficiaries. In 2026, LIS beneficiaries at 100% of the federal poverty level pay no more than $4.50 per generic fill and $11.20 per brand-name fill per month under the full LIS benchmark [10]. Because Prolia is dosed every six months, the per-fill cost under full LIS could be as low as $11.20 per injection, making this one of the most cost-effective pathways available to low-income Medicare patients in Louisiana.

Which Commercial Insurance Plans Cover Prolia (Denosumab) in Louisiana?

Most commercial insurers operating in Louisiana include denosumab on their specialty formularies, though tier placement and prior authorization requirements differ. Blue Cross and Blue Shield of Louisiana, Humana, Aetna, Cigna, and United Healthcare all list Prolia as a covered specialty drug as of 2026 formulary data, typically on Tier 4 or Tier 5 [11].

Prior authorization criteria commonly require documentation of a DEXA scan with T-score of -2.5 or lower, or a T-score of -1.0 to -2.5 with a FRAX 10-year major osteoporotic fracture probability at or above 20%, consistent with National Osteoporosis Foundation thresholds [12]. Physicians in Louisiana should submit the baseline DEXA report, fracture history, and any prior bisphosphonate therapy records with the PA request to reduce denial rates.

Step therapy is common. Several Louisiana commercial plans require documented failure or intolerance of an oral bisphosphonate (alendronate, risedronate) before approving Prolia. Patients with documented esophageal disease, chronic kidney disease with estimated GFR <35 mL/min/1.73 m², or prior bisphosphonate-related osteonecrosis of the jaw may qualify for step-therapy exception [13].

How Does the Amgen Savings Card Work in Louisiana?

Amgen offers the Prolia One Source savings program, which may reduce the out-of-pocket copay to $0 per dose for commercially insured patients who meet eligibility requirements. The program is not available to patients covered by any government-funded insurance, including Medicare, Medicaid, TRICARE, or VA benefits [14].

Eligibility requires commercial (employer-sponsored or individually purchased) insurance that covers Prolia. Patients must be residents of the United States, which includes Louisiana. The card is applied at the point of injection, either at the physician's office or at a participating specialty pharmacy. Annual benefit caps apply and are subject to change each January.

Louisiana patients can enroll online at amgen.com/onesource or by calling 1-800-772-6436. Enrollment is immediate and the savings typically activate within 24 to 48 hours. Physicians should verify current benefit caps at enrollment because Amgen adjusts program terms annually.

Are There Other Patient Assistance Programs for Prolia in Louisiana?

Beyond the Amgen savings card, Louisiana patients may access additional programs. Amgen Safety Net Foundation provides Prolia at no cost to uninsured or underinsured patients who meet income criteria, typically at or below 500% of the federal poverty level [15]. Applications require proof of income, a denial letter from insurance if applicable, and a completed physician attestation.

NeedyMeds.org and RxAssist.org both list manufacturer patient assistance program (PAP) details and maintain current eligibility thresholds. These databases are updated periodically and reflect any mid-year program changes by Amgen.

State pharmaceutical assistance programs in Louisiana are limited. Louisiana does not operate a standalone state pharmaceutical assistance program (SPAP) comparable to those in New York or Pennsylvania. However, the Louisiana Department of Health's 1-855-229-6848 helpline can connect patients to local health department resources and community health centers that may administer Prolia at reduced or no cost under 340B drug pricing [16].

Federally Qualified Health Centers (FQHCs) operating in Louisiana, including those in New Orleans, Baton Rouge, Shreveport, and Lafayette, purchase drugs at 340B prices, which represent a minimum 23.1% statutory discount off the Medicaid best price. For a drug with a list price of $1,500, the 340B ceiling price can be substantially lower, though FQHCs set their own patient charges [17].

Is Compounded Denosumab Legal in Louisiana?

Compounded denosumab from a 503A pharmacy is legal in Louisiana, and this represents a meaningful cost-reduction pathway for some patients. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare individualized drug preparations based on a valid patient-specific prescription from a licensed practitioner [18].

Louisiana's State Board of Pharmacy regulates 503A compounding pharmacies operating within the state. A licensed Louisiana prescriber can write a prescription for compounded denosumab specifying the same 60 mg/mL concentration used in Prolia, and a 503A pharmacy can prepare it. The legal basis for this practice rests on the compounding exemption as long as the pharmacy does not compound commercially available products in bulk for office stock, does not advertise compounded denosumab to the general public, and prepares only patient-specific quantities [19].

The FDA has not placed denosumab on its list of drug products that may not be compounded (the "503A Bulks" list as of 2026), meaning the compounding of denosumab for individual patients remains permissible under federal law [20].

Cost varies by 503A pharmacy. Some compounding pharmacies in Louisiana and those licensed to ship into Louisiana price compounded denosumab significantly below the Amgen list price. Patients considering this pathway should confirm that the compounding pharmacy holds a valid Louisiana Board of Pharmacy license, follows USP <797> sterile compounding standards, and sources API (active pharmaceutical ingredient) from an FDA-registered facility.

Clinicians should document the medical necessity for compounded denosumab in the patient record, particularly if the rationale involves cost or documented intolerance to excipients in the branded formulation. The American Society of Health-System Pharmacists (ASHP) position on compounding notes that "patient-specific compounding serves a legitimate role when commercially available products do not meet an individual patient's needs" [21].

One practical caution: the pharmacokinetic and pharmacodynamic equivalence of compounded denosumab to Prolia has not been established in a prospective head-to-head trial. Prescribers should counsel patients about this uncertainty and monitor bone mineral density with DEXA at 24 months regardless of which formulation is used, consistent with American Association of Clinical Endocrinology (AACE) monitoring guidance [22].

Can I Get a Prolia Prescription via Telehealth in Louisiana?

Telehealth prescribing of Prolia is permitted in Louisiana. Louisiana law allows licensed practitioners to prescribe Schedule V and non-controlled prescription drugs following a valid telehealth encounter that includes a real-time audio-visual evaluation, a review of relevant medical records, and documentation of clinical decision-making [23].

Prolia is not a controlled substance, so the additional DEA requirements governing controlled-substance telemedicine prescribing do not apply. A board-certified physician, nurse practitioner, or physician assistant practicing in Louisiana may initiate a Prolia prescription after a telehealth visit during which DEXA results, fracture risk assessment, and patient history are reviewed.

The injection itself requires an in-person clinical encounter or patient self-injection with proper training. Patients in rural Louisiana parishes, where endocrinologists and rheumatologists may not be locally available, can establish care via telehealth and receive the injection at a local primary care office, rural health clinic, or FQHC.

Louisiana's telehealth parity law (La. R.S. 22:1821) requires that commercial insurers reimburse telehealth services at the same rate as equivalent in-person services [24]. This parity does not extend to drug coverage decisions, but it does mean the prescribing visit itself should be covered at the same patient cost-sharing as an in-office endocrinology consultation.

What Are the Clinical Stakes of Choosing the Lowest-Cost Option?

Cost decisions around denosumab carry direct fracture-risk implications. A patient who starts denosumab and then stops due to cost, without transitioning to a bisphosphonate, faces a documented rebound fracture risk. The FREEDOM Extension data showed that patients who discontinued denosumab experienced rapid bone mineral density decline, and a subsequent analysis published in Osteoporosis International (N=1,001) found multiple vertebral fractures in 7.1% of patients within 12 months of discontinuation who had not received bridging antiresorptive therapy [4].

The American College of Rheumatology and AACE both recommend transitioning patients who discontinue denosumab to a bisphosphonate (typically zoledronic acid 5 mg IV within 6 months of the last injection) to preserve BMD gains [22]. That transition drug carries its own cost, roughly $250 to $600 for zoledronic acid infusion depending on site of service, but it is substantially lower than the fracture-related hospitalization cost.

Hip fracture hospitalization in Louisiana averages $32,000 to $48,000 depending on whether surgical repair is required, based on Louisiana Hospital Association cost data. Vertebral fracture management with kyphoplasty averages $15,000 to $25,000 per procedure [25]. From a cost-effectiveness standpoint, even the full list price of $3,000 per year for Prolia compares favorably to a single fracture hospitalization.

Prescribers should document shared decision-making conversations about cost and continuity. A patient who cannot reliably afford denosumab long-term may be better served by a bisphosphonate (alendronate 70 mg weekly costs roughly $10 to $20 per month at Louisiana retail pharmacies) as first-line therapy, with denosumab reserved for documented bisphosphonate intolerance or failure.

How Does Louisiana Compare to National Denosumab Access?

Louisiana's Medicaid exclusion for the osteoporosis indication is not unique nationally, but it is stricter than several other Southern states. Texas Medicaid, for comparison, allows denosumab under specific prior authorization criteria for high-risk osteoporosis patients who have failed bisphosphonates. Mississippi Medicaid also excludes the osteoporosis indication, while Florida Medicaid includes it with step therapy [26].

Nationally, the Institute for Clinical and Economic Review (ICER) 2020 osteoporosis evidence report found denosumab cost-effective at a threshold of $150,000 per quality-adjusted life year (QALY) gained for high-risk postmenopausal women, supporting its inclusion in state formularies from a health economics perspective [27]. Louisiana's exclusion persists despite that evidence base, making manufacturer programs and 503A compounding especially relevant for Louisiana patients.

Practical Steps for Louisiana Patients in 2026

Patients in Louisiana who need denosumab should work through the following sequence. First, confirm insurance status and request a formulary determination from the plan's pharmacy benefits manager. Second, if commercially insured, enroll in the Amgen One Source savings card before the first injection. Third, if Medicare Part B applies, confirm the administering provider bills Part B rather than routing through Part D. Fourth, if uninsured or Medicaid-only, contact the Amgen Safety Net Foundation and ask the prescribing physician about 340B-eligible facilities in the region. Fifth, discuss with the prescriber whether compounded denosumab from a Louisiana-licensed 503A pharmacy is clinically appropriate and cost-sustainable over the expected multi-year treatment duration.

Patients who receive denosumab injections every six months should schedule the next injection no later than 7 months after the prior dose. Delays beyond 7 months are associated with partial loss of BMD protection, according to post-hoc analyses of the FREEDOM Extension study [3].

A follow-up DEXA scan at 24 months of treatment is the standard monitoring interval per AACE 2020 Postmenopausal Osteoporosis guidelines, allowing assessment of treatment response before committing to indefinite continuation [22].